Stockscreener 앱 받기
4.49
0.22%
0.010
시간 외 거래:
4.48
-0.010
-0.22%
Oramed Pharmaceuticals Inc 주식(ORMP)의 최신 뉴스
Form 144 ORAMED PHARMACEUTICALS INC. For: 1 October By Investing.com - Investing.com Canada
An officer proposes selling 20,000 Oramed (ORMP) shares under a preset trading plan. - Stock Titan
A trading plan underpins an officer's proposed $140K share sale at Oramed (ORMP). - Stock Titan
40% of Oramed (ORMP) CFO’s stock award vests at grant; the rest vests over 24 months. - Stock Titan
Six option grants were canceled in exchange for a fully vested stock award to Oramed (ORMP) CEO Nadav Kidron. - Stock Titan
Type 2 Diabetes Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Ionis Pharma, Eli Lilly, Oramed Pharma, AstraZeneca, Novo Nordisk, Jiangsu - Barchart.com
Oramed Pharmaceuticals Inc.(NasdaqCM: ORMP) added to S&P Global BMI Index - marketscreener.com
Oramed Pharmaceuticals stock trades quietly as investors weigh recent trial progress - AD HOC NEWS
Oramed Pharmaceuticals Inc.Common Stock (Nasdaq:ORMP) Detailed Stock Data - The Chronicle-Journal
Form 8K Oramed Pharmaceuticals Inc For: 17 September By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals shareholders approve board, stock plan amendment at annual meeting - Investing.com
Oramed Pharmaceuticals (ORMP) moves to three-year pay votes - Stock Titan
Oramed shifts focus to investments, sees gains but faces cash and dilution risks - Pluang
Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP) - Seeking Alpha
Oramed Pharmaceuticals (ORMP) Slips to $4.76, Holding Above $4.52 SupportLate Stage Breakouts - siam.in
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) Share Price, ORMP Stock News, ORMP Share Price & Updates - Kalkine
Oramed backs exoskeleton maker Lifeward (NASDAQ: LFWD) in milestone-based funding deal - Stock Titan
Oramed Pharmaceuticals (ORMP) Rises 3.2% to $5.0, Testing Key $5.25 ResistanceTPO Profile - vinanet.vn
Oramed Pharmaceuticals stock holds at $5 after recent biotech volatility - ad-hoc-news.de
Oramed Pharmaceuticals Inc. (ORMP) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness - Yahoo Finance
Oramed Pharmaceuticals Incorporated Actuals & Estimates (TRADEGATE:OJU1) - TradingView
Top Penny Stocks To Watch In August 2026 - simplywall.st
Oramed (ORMP) EPS and Revenue: Profit Per Share Surpasses Its Benchmark in the Latest Reading; Post-Earnings: The Stock Ends Up 4.60% on the DayDividend Earnings Report - vinanet.vn
Nano Dimension Names Nadav Kidron to Board, Exclusivity with Infinite Epigenetics Ends - Kalkine Media
Nano Dimension Appoints Nadav Kidron to Lead Capital Allocation Review - citybiz
Oramed CEO Joins Nano Dimension Board as Directors Weigh Capital Options - Stock Titan
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee - The Manila Times
MSN Money - MSN
ORMP Price Today: Oramed Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded by Wall Street Zen to Buy Rating - MarketBeat
Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A - Stock Titan
ORMP Q4 2025 Earnings: EPS Beat Drives Stock Gain as Revenue Remains N/AReturn On Assets - vinanet.vn
Oramed Pharmaceuticals (NASDAQ:ORMP) Releases Quarterly Earnings Results - marketbeat.com
Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a shareEarnings Preview - TradingView
Oramed: Q2 Earnings Snapshot - marketscreener.com
ORAMED PHARMACEUTICALS INC. 2Q 2026: Revenue $0 Net income $78.16M, EPS $1.84— 10-Q Summary - TradingView
Oramed Pharmaceuticals (NASDAQ: ORMP) pivots to investment model with $116M profit - Stock Titan
Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Oramed Pharmaceuticals (ORMP) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Above 200 Day Moving AverageWhat's Next? - MarketBeat
Oramed Pharmaceuticals (ORMP) Holds Steady at $4.33 as Range-Bound Trading PersistsSpring Pattern - dars.gov.et
ORMP | Oramed Pharmaceuticals Inc. Executive Compensation - Quiver Quantitative
ORMP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Oramed Pharmaceuticals announces annual shareholder meeting - Bitget
ORAMED PHARMACEUTICALS INC. SEC Filing (Aug 3, 2026) | ORMP ARS - Stock Titan
ORMP Q4 2025 Earnings: Profitable Quarter on Non-Operating Income as Stock RisesEstimate Revision Count - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Oramed Pharmaceuticals Inc (ORMP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Cash Flow - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Balance Sheet - TradingKey
ORMP Q4 2025 Earnings: EPS Surges Past Estimates Despite Revenue Absence, Stock Declines 3.13%Earnings Forecast Report - dars.gov.et
ORMP|Oramed Pharmaceuticals Inc|Price:4.762|Chg%:+0.192 - TradingKey
Oramed Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:ORMP - TradingView
TradingKey - TradingKey
Oramed Pharmaceuticals Inc (ORMP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oramed Pharmaceuticals Inc (OJU1.SG) stock price, news, quote and history - Yahoo Finance UK
Nano Dimension Ltd. (NASDAQ: NNDM) sees Oramed stake drop to 3.3% - Stock Titan
0.05%
0.82%
자본화:
|
볼륨(24시간):